Medline (NASDAQ:MDLN) Raised to Hold at BNP Paribas

Medline (NASDAQ:MDLN) was upgraded by stock analysts at BNP Paribas to a “hold” rating in a research note issued on Monday,Zacks.com reports.

A number of other analysts have also recently weighed in on MDLN. Leerink Partners started coverage on Medline in a research report on Monday. They set an “outperform” rating and a $48.00 price target on the stock. Royal Bank Of Canada began coverage on Medline in a research note on Monday. They issued an “outperform” rating and a $47.00 target price on the stock. Citigroup assumed coverage on shares of Medline in a report on Monday. They issued a “buy” rating and a $48.00 price objective on the stock. Wells Fargo & Company assumed coverage on shares of Medline in a research note on Monday. They set an “equal weight” rating and a $42.00 target price for the company. Finally, TD Cowen initiated coverage on Medline in a research report on Monday. They set a “buy” rating and a $46.00 price objective for the company. Two analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat, Medline currently has an average rating of “Moderate Buy” and an average target price of $46.70.

Medline Trading Up 0.7%

MDLN traded up $0.32 on Monday, hitting $43.17. 655,403 shares of the company’s stock were exchanged, compared to its average volume of 4,944,748. Medline has a twelve month low of $34.89 and a twelve month high of $45.50.

Insider Buying and Selling at Medline

In other news, Director Charles N. Mills purchased 2,579,310 shares of the stock in a transaction dated Thursday, December 18th. The shares were bought at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the transaction, the director owned 2,441,379 shares in the company, valued at $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of the company’s stock in a transaction dated Thursday, December 18th. The stock was purchased at an average cost of $29.00 per share, for a total transaction of $74,999,974.00. Following the purchase, the director directly owned 2,586,206 shares in the company, valued at approximately $74,999,974. This represents a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure.

Key Stories Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Multiple Wall Street firms have initiated coverage with bullish ratings and above‑market price targets (examples include Truist $52, Evercore/BTIG $50, Goldman Sachs $49 and Sanford Bernstein outperform), signaling strong analyst conviction in Medline’s growth story and supporting upside. Analysts Say Medline Has The Secret Sauce For Sustained Growth
• Positive Sentiment: Major brokerage houses and research teams have broadly initiated coverage (Deutsche Bank, JPMorgan, Jefferies, Wells Fargo, Citigroup, Barclays, TD Cowen, Wolfe Research, Mizuho, Rothschild/Redburn and others), which increases visibility and liquidity for MDLN stock and often supports higher trading interest. Medline Coverage Initiated at Deutsche Bank
• Positive Sentiment: Medline’s IPO and market debut were sizable — the company raised roughly $7 billion and saw strong early market interest, which underpins many analysts’ bullish forecasts tied to its product portfolio and scale. IPO/market debut coverage
• Neutral Sentiment: Coverage/press pieces are discussing valuation and whether MDLN is fairly priced after early stability; these analyses add context but don’t change near‑term fundamentals. Is Medline Fairly Priced
• Neutral Sentiment: Some articles in news streams appear mis‑tagged (e.g., a MarketBeat IPO piece focused on Aktis Oncology was associated with MDLN); exercise caution when treating aggregated headlines as firm‑specific signals. A Fresh IPO That Long-Term Investors Shouldn’t Ignore
• Neutral Sentiment: Reported short‑interest data for January appears inconsistent/insignificant (effectively 0 days on available figures), so short pressure is not a current driver based on those numbers.
• Negative Sentiment: A few firms issued neutral/hold recommendations (e.g., BNP Paribas, Rothschild Redb with hold ratings), which could limit upside momentum compared with the many buy/strong‑buy calls. Analyst notes (Zacks)

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.